Descrizione del progetto
Un’inversione di tendenza nella resistenza antimicrobica
La resistenza antimicrobica rappresenta la più grande minaccia per la salute globale; molte infezioni stanno diventando più difficili da trattare, poiché gli antibiotici diventano meno efficaci. La sepsi colpisce più persone del cancro ai polmoni, al seno e alla prostata messi insieme, si sviluppa rapidamente e attacca più organi, spesso portando allo shock settico e alla morte. L’azienda svedese Gradientech intende sviluppare e introdurre nella pratica clinica uno strumento diagnostico ultra-rapido per i test di suscettibilità antibiotica basato su una piattaforma tecnologica proprietaria. L’innovativo strumento combina la microfluidica avanzata con il rilevamento e l’analisi continua delle immagini e ridurrà il tempo dei test di suscettibilità antibiotica a 2 ore. Il progetto QuickMIC, finanziato dall’UE, svilupperà un piano aziendale per i futuri studi clinici e le attività di commercializzazione.
Obiettivo
The aim of the project is to bring QuickMIC™, an ultra-rapid diagnostic tool for Antibiotic Susceptibility Testing (AST) to the market and clinical practice. AST is usually carried out to determine which antibiotic will be the most appropriate in treating a bacterial infection in a particular patient. Sepsis is the major cause of death as a result of an infection today. It affects approx. 30 million of people every year worldwide. About 20 % of the patients do not survive the disease. Currently, it can take up to 48 hours for the current golden standard AST method to produce reliable diagnostic results. Therefore, doctors empirically treat sepsis patients with wide-spectrum antibiotics while the blood samples are being tested. The globally escalating antimicrobial resistance (AMR) has resulted in empirical treatment being unsuccessful more and more often. Misuse of antibiotics additionally contributes to increasing resistance. The improvement of survival rates in sepsis and the decrease in AMR will only be possible with access to a quicker AST tool. To address this unmet clinical need, Gradientech is developing an ultra-rapid AST system, QuickMIC™, based on a patented technology platform. By combining i) advanced microfluidics and ii) continuous image detection and analysis, QuickMIC™ can reduce the time of an AST to two hours. Besides being the fastest AST under development, QuickMIC™ is also a low-price alternative compared to its direct competitors. By commercializing QuickMIC™, Gradientech will make an important contribution to fighting AMR in Europe. Moreover, we will significantly improve the diagnosis and treatment of sepsis. A continued development of QuickMIC™ will result in a CE-IVD marking by early 2019. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation activities. If successful, the overall innovation effort will take Gradientech to a new level of competitiveness and growth.
Campo scientifico
- medical and health sciencesclinical medicinesurgery
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
75183 UPPSALA
Svezia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.